{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:09:41Z","timestamp":1784038181070,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Middle-aged and Young People\u2019s Health Science, Technology Innovation Excellent Youth Talent Project","award":["YXKC2021053"],"award-info":[{"award-number":["YXKC2021053"]}]},{"name":"Henan Medical Science and Technology Research and Development Program Project","award":["SBGJ202402034"],"award-info":[{"award-number":["SBGJ202402034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08881-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:58:00Z","timestamp":1758887880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The downregulation of ubiquitin-specific peptidase 2 indicates a poor prognosis and promotes the progression of gastric cancer through focal adhesion and ECM pathway signaling"],"prefix":"10.1038","volume":"15","author":[{"given":"Yingjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingke","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"8881_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"8881_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.suc.2020.02.004","volume":"100","author":"H Hoshi","year":"2020","unstructured":"Hoshi, H. Management of gastric adenocarcinoma for general surgeons. Surg. Clin. North. Am. 100 (3), 523\u2013534 (2020).","journal-title":"Surg. Clin. North. Am."},{"issue":"6","key":"8881_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/MOG.0000000000000679","volume":"36","author":"DH Ilson","year":"2020","unstructured":"Ilson, D. H. Advances in the treatment of gastric cancer. Curr. Opin. Gastroenterol. 36 (6), 525\u2013529 (2020).","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"8881_CR4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/curroncol29030131","volume":"29","author":"A H\u00f6gner","year":"2022","unstructured":"H\u00f6gner, A. & Moehler, M. Immunotherapy in gastric Cancer. Curr. Oncol. 29 (3), 1559\u20131574 (2022).","journal-title":"Curr. Oncol."},{"key":"8881_CR5","doi-asserted-by":"crossref","unstructured":"Kitamura, H. & Hashimoto, M. USP2-Related cellular signaling and consequent pathophysiological outcomes. Int J. Mol. Sci 22(3). (2021).","DOI":"10.3390\/ijms22031209"},{"issue":"2","key":"8881_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/iub.300","volume":"62","author":"JJ Sacco","year":"2010","unstructured":"Sacco, J. J., Coulson, J. M., Clague, M. J. & Urb\u00e9, S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 62 (2), 140\u2013157 (2010).","journal-title":"IUBMB Life"},{"key":"8881_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12894-015-0074-x","volume":"15","author":"P Jeong","year":"2015","unstructured":"Jeong, P. et al. Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. BMC Urol. 15, 80 (2015).","journal-title":"BMC Urol."},{"issue":"7","key":"8881_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/carcin\/bgu015","volume":"35","author":"CL Wang","year":"2014","unstructured":"Wang, C. L. et al. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma. Carcinogenesis 35 (7), 1500\u20131509 (2014).","journal-title":"Carcinogenesis"},{"issue":"9","key":"8881_CR9","first-page":"1823","volume":"8","author":"J Kim","year":"2018","unstructured":"Kim, J., Alavi Naini, F., Sun, Y. & Ma, L. Ubiquitin-specific peptidase 2a (USP2a) deubiquitinates and stabilizes \u03b2-catenin. Am. J. Cancer Res. 8 (9), 1823\u20131836 (2018).","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"8881_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4161\/cc.11.6.19550","volume":"11","author":"J Kim","year":"2012","unstructured":"Kim, J., Kim, W. J., Liu, Z., Loda, M. & Freeman, M. R. The ubiquitin-specific protease USP2a enhances tumor progression by targeting Cyclin A1 in bladder cancer. Cell. Cycle. 11 (6), 1123\u20131130 (2012).","journal-title":"Cell. Cycle"},{"issue":"Pt 2","key":"8881_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semcancer.2020.01.012","volume":"67","author":"S Qie","year":"2020","unstructured":"Qie, S. & Diehl, J. A. Cyclin D degradation by E3 ligases in cancer progression and treatment. Semin Cancer Biol. 67 (Pt 2), 159\u2013170 (2020).","journal-title":"Semin Cancer Biol."},{"issue":"18","key":"8881_CR12","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1038\/s41388-022-02275-0","volume":"41","author":"Y Tu","year":"2022","unstructured":"Tu, Y. et al. Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-\u03b2 signaling. Oncogene 41 (18), 2597\u20132608 (2022).","journal-title":"Oncogene"},{"issue":"6","key":"8881_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38 (6), 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"8881_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16 (5), 284\u2013287 (2012).","journal-title":"Omics"},{"issue":"6","key":"8881_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell. Syst. 1 (6), 417\u2013425 (2015).","journal-title":"Cell. Syst."},{"issue":"7","key":"8881_CR16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43 (7), e47 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"8881_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12885-020-07235-z","volume":"20","author":"H Jiang","year":"2020","unstructured":"Jiang, H., Xu, S. & Chen, C. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma. BMC Cancer. 20 (1), 782 (2020).","journal-title":"BMC Cancer"},{"issue":"1","key":"8881_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","volume":"17","author":"AN Kamarudin","year":"2017","unstructured":"Kamarudin, A. N., Cox, T. & Kolamunnage-Dona, R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med. Res. Methodol. 17 (1), 53 (2017).","journal-title":"BMC Med. Res. Methodol."},{"issue":"Database issue","key":"8881_CR19","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41 (Database issue), D955\u2013961 (2013).","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"8881_CR20","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher, P., Cox, N. & Huang, R. S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 9 (9), e107468 (2014).","journal-title":"PLoS One"},{"issue":"14","key":"8881_CR21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/bioinformatics\/btt269","volume":"29","author":"K Yang","year":"2013","unstructured":"Yang, K. et al. CMAP: complement map database. Bioinformatics 29 (14), 1832\u20131833 (2013).","journal-title":"Bioinformatics"},{"issue":"11","key":"8881_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park, J., Cho, J. & Song, E. J. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch. Pharm. Res. 43 (11), 1144\u20131161 (2020).","journal-title":"Arch. Pharm. Res."},{"key":"8881_CR23","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan, S. et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist. Updat. 48, 100663 (2020).","journal-title":"Drug Resist. Updat"},{"key":"8881_CR24","doi-asserted-by":"crossref","unstructured":"Zhang, S. et al. Targeting the deubiquitinase USP2 for malignant tumor therapy (Review). Oncol Rep 50(4). (2023).","DOI":"10.3892\/or.2023.8613"},{"key":"8881_CR25","doi-asserted-by":"publisher","first-page":"102104","DOI":"10.1016\/j.tranon.2024.102104","volume":"49","author":"F Xu","year":"2024","unstructured":"Xu, F. et al. The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression. Transl Oncol. 49, 102104 (2024).","journal-title":"Transl Oncol."},{"issue":"6","key":"8881_CR26","first-page":"504","volume":"23","author":"Y Yang","year":"2007","unstructured":"Yang, Y. et al. [Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23 (6), 504\u2013506 (2007).","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"9","key":"8881_CR27","first-page":"5670","volume":"12","author":"D Li","year":"2020","unstructured":"Li, D., Bao, J., Yao, J. & Li, J. LncRNA USP2-AS1 promotes colon cancer progression by modulating Hippo\/YAP1 signaling. Am. J. Transl Res. 12 (9), 5670\u20135682 (2020).","journal-title":"Am. J. Transl Res."},{"key":"8881_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/PPA.S235430","volume":"14","author":"EM Janssen","year":"2020","unstructured":"Janssen, E. M. et al. Analysis of patient preferences in lung Cancer - Estimating acceptable tradeoffs between treatment benefit and side effects. Patient Prefer Adherence. 14, 927\u2013937 (2020).","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"8881_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.21037\/atm.2020.02.141","volume":"8","author":"X Meng","year":"2020","unstructured":"Meng, X. et al. Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression. Ann. Transl Med. 8 (6), 319 (2020).","journal-title":"Ann. Transl Med."},{"issue":"47","key":"8881_CR30","doi-asserted-by":"publisher","first-page":"24628","DOI":"10.1074\/jbc.M116.738567","volume":"291","author":"MI Davis","year":"2016","unstructured":"Davis, M. I. et al. Small molecule Inhibition of the Ubiquitin-specific protease USP2 accelerates Cyclin D1 degradation and leads to cell cycle arrest in colorectal Cancer and mantle cell lymphoma models. J. Biol. Chem. 291 (47), 24628\u201324640 (2016).","journal-title":"J. Biol. Chem."},{"issue":"30","key":"8881_CR31","doi-asserted-by":"publisher","first-page":"48391","DOI":"10.18632\/oncotarget.10268","volume":"7","author":"T Wei","year":"2016","unstructured":"Wei, T. et al. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget 7 (30), 48391\u201348400 (2016).","journal-title":"Oncotarget"},{"issue":"3","key":"8881_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.26124","volume":"129","author":"M Metzig","year":"2011","unstructured":"Metzig, M. et al. An RNAi screen identifies USP2 as a factor required for TNF-\u03b1-induced NF-\u03baB signaling. Int. J. Cancer. 129 (3), 607\u2013618 (2011).","journal-title":"Int. J. Cancer"},{"issue":"3\u20134","key":"8881_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3727\/000000003108749053","volume":"11","author":"N Gousseva","year":"2003","unstructured":"Gousseva, N. & Baker, R. T. Gene structure, alternate splicing, tissue distribution, cellular localization, and developmental expression pattern of mouse deubiquitinating enzyme isoforms Usp2-45 and Usp2-69. Gene Expr. 11 (3\u20134), 163\u2013179 (2003).","journal-title":"Gene Expr"},{"issue":"10","key":"8881_CR34","first-page":"4746","volume":"11","author":"C Nadolny","year":"2021","unstructured":"Nadolny, C. et al. Dysregulation and activities of ubiquitin specific peptidase 2b in the pathogenesis of hepatocellular carcinoma. Am. J. Cancer Res. 11 (10), 4746\u20134767 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"8881_CR35","doi-asserted-by":"publisher","first-page":"882372","DOI":"10.3389\/fonc.2022.882372","volume":"12","author":"SP Chen","year":"2022","unstructured":"Chen, S. P. et al. LncRNA USP2-AS1 promotes hepatocellular carcinoma growth by enhancing YBX1-Mediated HIF1\u03b1 protein translation under hypoxia. Front. Oncol. 12, 882372 (2022).","journal-title":"Front. Oncol."},{"key":"8881_CR36","doi-asserted-by":"crossref","unstructured":"Stanton, S. E., Castle, P. E., Finn, O. J., Sei, S. & Emens, L. A. Advances and challenges in cancer Immunoprevention and immune interception. J Immunother Cancer 12(3). (2024).","DOI":"10.1136\/jitc-2023-007815"},{"issue":"7","key":"8881_CR37","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1007\/s13277-015-3207-7","volume":"36","author":"Q Qu","year":"2015","unstructured":"Qu, Q. et al. USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Tumour Biol. 36 (7), 5415\u20135423 (2015).","journal-title":"Tumour Biol."},{"issue":"4","key":"8881_CR38","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.jbc.2021.101109","volume":"297","author":"F Zhang","year":"2021","unstructured":"Zhang, F., Zhao, Y. & Sun, Y. USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates. J. Biol. Chem. 297 (4), 101109 (2021).","journal-title":"J. Biol. Chem."},{"key":"8881_CR39","doi-asserted-by":"crossref","unstructured":"Statement of removal. Cell. Cycle 14(5):784. (2015).","DOI":"10.1080\/15384101.2015.1018741"},{"issue":"3","key":"8881_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1535-6108(04)00055-8","volume":"5","author":"E Graner","year":"2004","unstructured":"Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 5 (3), 253\u2013261 (2004).","journal-title":"Cancer Cell."},{"issue":"1","key":"8881_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-018-0850-z","volume":"37","author":"J Shen","year":"2018","unstructured":"Shen, J. et al. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1\/FAK signalling in breast cancer. J. Exp. Clin. Cancer Res. 37 (1), 175 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"13","key":"8881_CR42","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.7150\/ijbs.76425","volume":"18","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. CPNE8 promotes gastric Cancer metastasis by modulating focal adhesion pathway and tumor microenvironment. Int. J. Biol. Sci. 18 (13), 4932\u20134949 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"8881_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Ther. 146, 132\u2013149 (2015).","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"8881_CR44","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer. 14 (9), 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"8881_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","volume":"12","author":"X Tan","year":"2023","unstructured":"Tan, X. et al. Focal adhesion kinase: from biological functions to therapeutic strategies. Exp. Hematol. Oncol. 12 (1), 83 (2023).","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"8881_CR46","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2007.05.041","volume":"129","author":"D Lietha","year":"2007","unstructured":"Lietha, D. et al. Structural basis for the autoinhibition of focal adhesion kinase. Cell 129 (6), 1177\u20131187 (2007).","journal-title":"Cell"},{"issue":"2","key":"8881_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.drudis.2021.11.025","volume":"27","author":"PA Quispe","year":"2022","unstructured":"Quispe, P. A., Lavecchia, M. J. & Le\u00f3n, I. E. Focal adhesion kinase inhibitors in the treatment of solid tumors: preclinical and clinical evidence. Drug Discov Today. 27 (2), 664\u2013674 (2022).","journal-title":"Drug Discov Today"},{"issue":"4","key":"8881_CR48","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.cellin.2022.100047","volume":"1","author":"R An","year":"2022","unstructured":"An, R. et al. USP2 promotes experimental colitis and bacterial infections by inhibiting the proliferation of myeloid cells and remodeling the extracellular matrix network. Cell. Insight. 1 (4), 100047 (2022).","journal-title":"Cell. Insight"},{"issue":"2","key":"8881_CR49","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/jcmm.16162","volume":"25","author":"Q Xu","year":"2021","unstructured":"Xu, Q. et al. Ubiquitin-specific protease 2 regulates Ang II-induced cardiac fibroblasts activation by up-regulating Cyclin D1 and stabilizing \u03b2-catenin in vitro. J. Cell. Mol. Med. 25 (2), 1001\u20131011 (2021).","journal-title":"J. Cell. Mol. Med."}],"updated-by":[{"DOI":"10.1038\/s41598-026-59942-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08881-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:03:04Z","timestamp":1784037784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08881-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8881"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08881-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-59942-5","URL":"https:\/\/doi.org\/10.1038\/s41598-026-59942-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Affiliated Cancer Hospital of Zhengzhou University (Ethics Review Number: 2020012) and conformed to the provisions of the Declaration of Helsinki. Informed Consent: All patients provided written informed consent. Registry and registration no. of studies\/trials: N\/A. Animal studies: N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"33308"}}